Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386945 | 0.86 | APP (0.64) | APPMAPTHTTGFERHSD17B10 | |
| SCHEMBL2374131 | 0.85 | APP (0.63) | APPGABRA5SYK | |
| SCHEMBL2373702 | 0.85 | APP (0.63) | APPMAPTSYK | |
| SCHEMBL2373284 | 0.82 | APP (0.41) | APPHSD17B10GABRA5 | |
| SCHEMBL2373666 | 0.75 | APP (0.37) | APPMAPTHTTGFERHSD17B10 | |
| SCHEMBL2374723 | 0.75 | APP (1.00) | APPMAPTHTTGFERHSD17B10 | |
| SCHEMBL2374726 | 0.75 | APP (1.00) | APPMAPTHTTGFERHSD17B10 | |
| SCHEMBL2374189 | 0.73 | APP (0.65) | APPMAPT | |
| SCHEMBL2374229 | 0.73 | APP (0.65) | APPMAPT | |
| SCHEMBL2373975 | 0.71 | APP (0.64) | APPMAPTHTTGFERHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363392-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-1999109-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2363391-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363392-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7687052-B2 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | APP, PSEN1, HTT | APP 1/4885MAPT 6/4885HTT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.